B. Riley Predicts Increased Earnings for X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at B. Riley boosted their FY2024 EPS estimates for shares of X4 Pharmaceuticals in a research report issued on Monday, November 18th. B. Riley analyst K. Patel now forecasts that the company will earn ($0.17) per share for the year, up from their prior estimate of ($0.68). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.67) per share. B. Riley also issued estimates for X4 Pharmaceuticals’ FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.16) EPS.

XFOR has been the subject of several other research reports. HC Wainwright dropped their price target on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Stifel Nicolaus dropped their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th.

X4 Pharmaceuticals Trading Down 7.5 %

Shares of XFOR opened at $0.34 on Wednesday. X4 Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.60. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The company has a market capitalization of $58.06 million, a P/E ratio of -4.09 and a beta of 0.39. The firm’s 50 day simple moving average is $0.57 and its 200 day simple moving average is $0.73.

Insider Buying and Selling

In related news, CEO Paula Ragan sold 239,436 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $131,689.80. Following the transaction, the chief executive officer now directly owns 1,057,713 shares in the company, valued at approximately $581,742.15. This represents a 18.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Adam S. Mostafa sold 230,645 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 580,800 shares of company stock worth $321,447. Insiders own 1.62% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in XFOR. Verition Fund Management LLC bought a new stake in X4 Pharmaceuticals during the 3rd quarter valued at $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth approximately $37,000. Price T Rowe Associates Inc. MD grew its stake in X4 Pharmaceuticals by 46.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after purchasing an additional 12,514 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of X4 Pharmaceuticals during the second quarter valued at about $65,000. Finally, Rhumbline Advisers lifted its position in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after buying an additional 23,831 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.